Recombinant Human Melanoma antigen preferentially expressed in tumors (PRAME)

^{In Stock}

中文名稱：

人PRAME重組蛋白
貨號：

CSB-EP018603HU
規格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

PRAME
Uniprot No.：

P78395
別名：

4930534P07Rik; Cancer/testis antigen 130; CT130; MAPE; Melanoma antigen preferentially expressed in tumors; OIP 4; OIP-4; OIP4 ; OPA interacting protein 4; Opa interacting protein OIP4; OPA-interacting protein 4; PRAME; PRAME_HUMAN; Preferentially expressed antigen in melanoma ; Preferentially expressed antigen of melanoma; RP23-250F8.3
種屬：

Homo sapiens (Human)
蛋白長度：

Full Length
來源：

E.coli
分子量：

61.9kDa
表達區域：

1-509aa
氨基酸序列

MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal 6xHis-tagged
產品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
產品描述：

CUSABIO transfected the expression vector which inserted the recombinant DNA into the E.coli, cultured the cells, and then induced the transcription and translation of the cloned vector. The N-terminal 6xHis tag sequence was appended to the gene coding for the E.coli of the human PRAME protein to form the recombinant DNA. The recombinant human PRAME was expressed as N-terminal 6xHis-tagged fusion. The purity of the protein is greater than 90% assayed by SDS-PAGE. It has an apparent molecular weight of approximately 55 kDa.
PRAME is a tumor-associated antigen, which belongs to the family of cancer–testis antigens. Gene PRAME was found to encode an antigen recognized on a human melanoma cell line by an autologous cytolytic T-lymphocyte clone. This gene is expressed at a high level in a very large fraction of tumours, such as melanomas, non-small-cell lung carcinomas, sarcomas, head and neck tumours and renal carcinomas. It is therefore a candidate for tumour immunotherapy even though some low expression is found in certain normal tissues. Although diffuse immunoreactivity for PRAME is found in most primary cutaneous melanomas, melanocytic nevi express PRAME usually only in a subpopulation of tumor cells. In addition, studies have shown that unlike the MAGE, GAGE and BAGE genes, PRAME was expressed at a significant level in peripheral blood or bone marrow samples from patients with a malignant blood disease.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation. The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding. In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation. Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
基因功能參考文獻：
1. Knockdown PRAME in HCC cells, increased cell apoptosis was correlated with the proportion of cells in G0/G1 stage, activated p53 mediated apoptosis, and increased cyclin p21 expression. PMID: 29439259
2. PRAME is frequently expressed in epithelial ovarian cancer at the mRNA and protein levels, and DNA methylation is a key mechanism regulating its expression. PMID: 27322684
3. PRAME is aberrantly hypomethylated and activated in Class 1 and Class 2 uveal melanomas and is associated with increased metastatic risk in both classes PMID: 27486988
4. To investigate the impact of gene copy number variation on PRAME expression, plasma cells were sorted from 50 newly diagnosed multiple myeloma patients and 8 healthy volunteers to measure PRAME transcript levels and gene copy numbers by real-time quantitative polymerase chain reaction. PMID: 28953414
5. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. PMID: 28634046
6. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
7. PRAME plays a role in preventing the invasion and metastasis of lung adenocarcinoma PMID: 27391090
8. PRAME is expressed in many primary and metastatic UMs, and about half of the metastatic UMs coexpress PRAME and HLA class I. PMID: 28448663
9. PRAME is a downstream factor of SOX17 and LIN28 in regulating pluripotency and suppressing somatic/germ cell differentiation in primordial germ cells, germ cell neoplasia in situ, and seminomas. PMID: 27441500
10. In line with its roles in controlling cell growth, RPAME regulates multiple critical cell-growth related genes, including IGF1R oncogene. IGF1R up-regulation contributes to increase of cell growth upon the knockdown of PRAME. PMID: 27241212
11. This study demonstrates that PRAME functions as a tumor suppressor in breast cancer. PMID: 27632898
12. PRAME is an independent prognostic biomarker in Uveal melanoma , which identifies increased metastatic risk in patients with Class 1 or disomy 3 tumors. PMID: 26933176
13. Leukemias expressing high levels of PRAME had higher levels of cell death by regulating S100A4/p53 signaling. PMID: 27049257
14. Our results suggest that the leukemias expressing high levels of PRAME has favorable prognosis PMID: 26823776
15. PRAME expression is considered as a poor prognostic parameter in HL. PMID: 26044287
16. PRAME immunoreactivity in myeloid leukemia (ML) of Down syndrome (DS) is largely due to the non-blast components, while PRAME immunoreactivity in blasts of Transient abnormal myelopoiesis (TAM) is not restricted to cases that progress to ML of DS. PMID: 25887863
17. This study shows the prognostic significance of PRAME expression in diffuse large B-cell lymphoma patients treated with R-CHOP therapy. PMID: 24820636
18. results suggested that PRAME was a predictor for better outcome, could be a useful target for immunotherapy, and might represent a candidate marker for the monitoring of minimal residual disease PMID: 24600975
19. elevated PRAME expression in head and neck squamous cell carcinoma PMID: 23905893
20. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in MDS. PMID: 23110703
21. PRAME impairs differentiation and increases proliferation likely via blocking retinoic acid receptor signaling. PMID: 23444226
22. PRAME is upregulated by signalling pathways that are activated in response to infection/inflammation. PMID: 23460923
23. The complex PRAME/EZH2 is able to repress TRAIL expression, in a cancer-specific manner; inhibition of PRAME/EZH2 releases apoptosis-mediating TRAIL. (Review) PMID: 23228130
24. PRAME and its paralogs are leucine rich repeat proteins. Structure predictions suggest PRAME resembles the extracellular domains of TLR3 and TLR4, or intracellular NALP family. This suggests PRAME may have a role in sensing Pathogen Associated Molecular Patterns (PAMPs). PMID: 23460923
25. PRAME expression in leukaemic cell lines is upregulated by IFN gamma and LPS, suggesting a possible role in immune responses. PRAME associates with Elongin BC complexes by binding Elongin C, and co-localises to the Golgi network. Nuclear PRAME interacts with Histone H3. The results suggest that PRAME has dual roles in gene regulation in the nucleus and protein turnover trafficking in the Golgi PMID: 23460923
26. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PMID: 23409080
27. a novel link between the oncoprotein PRAME and the conserved EKC complex PMID: 22912744
28. PRAME as biomarkers for solid tumor PMID: 23075240
29. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine PMID: 22384167
30. PRAME expression is regulated at the epigenetic level. For this reason inhibitors of DNA methylation, such as 5-azacytidine, can modulate the expression of this tumor associated antigen. PMID: 22503131
31. Studies suggest that activated human gammadelta T cells can efficiently present PRAME and STEAP1-derived epitopes and allow breaking tolerance against these tumor-associated self-antigens. PMID: 21928126
32. these results suggest that PRAME plays an important role in cell proliferation and disease progression in osteosarcoma. PMID: 22390931
33. the expansion of the PRAME family occurred in both autosomes and sex chromosomes PMID: 21347312
34. PRAME effectively differentiates mullerian carcinoma from malignant mesothelioma at the mRNA and protein levels. PMID: 22261449
35. PRAME expression might be related to distinct patterns of tumorigenesis PMID: 21691740
36. PRAME plays an important role in disease progression in acute leukemia. PMID: 21550659
37. The authors applied protein-complex purification strategies and identified PRAME as a substrate recognition subunit of a Cullin2-based E3 ubiquitin ligase. PMID: 21822215
38. The level of prame gene transcript increases in chronic myeloid leukemia which associates with disease progression. PMID: 20723287
39. The cytotoxic activity of our PRAME-specific CTLs was directed not only against leukemic blasts, but also against leukemic progenitor cells as assessed by colony-forming-inhibition assays, which have been implicated in leukemia relapse. PMID: 21278353
40. PRAME may be involved in the tumorigenic process in a wide range of cancers, at least in part by blocking the tumor suppressor pathway mediated by TRAIL expression. PMID: 20838376
41. Results showed the expression of MCSP and PRAME in conjunctival melanoma and benign conjunctival nevi and showed that MCSP and PRAME were differentially expressed in both and can help to differentiate the lesions diagnostically. PMID: 20805128
42. The PRAME transcript was highly expressed in acute myeloid leukemia patients and was a favorable marker of prognosis. PMID: 20376794
43. PRAME mRNA could be used to monitor minimal residual disease in newly diagnosed acute myeloid leukemia patients. PMID: 19035174
44. E2F4, PHACTR3, PRAME family member and CDH12 most probably play important role in non-small-cell lung cancer geneses PMID: 19473719
45. expression of PRAME is an indicator of favorable prognosis and could be a useful tool for monitoring minimal residual disease in childhood AML. PMID: 11943337
46. PRAME gene expression in childhood acute lymphoblastic leukemia PMID: 12419593
47. PRAME is highly expressed in primary advanced neuroblastoma PMID: 15240516
48. The overexpression of PRAME protein frequently observed in human cancers confers growth or survival advantages by antagonizing retinoic acid receptor(RAR) signaling. PMID: 16179254
49. The results suggest that the analysis of PRAME protein may contribute for the distinction between normal and leukemic cells in chronic lymphoproliferative disorders(CLD), and that PRAME may be a potential target for therapy. PMID: 16620968
50. PRAME is expressed in acute myeloblastic leukaemia PMID: 16681423
顯示更多

收起更多
亞細胞定位：

Nucleus. Chromosome. Cytoplasm. Golgi apparatus. Cell membrane.
蛋白家族：

PRAME family
組織特異性：

Expressed in testis. Detected in samples of kidney, brain and skin.
數據庫鏈接：

HGNC: 9336

OMIM: 606021

KEGG: hsa:23532

STRING: 9606.ENSP00000381726

UniGene: Hs.30743